Levetiracetam Krka (Levetiracetam)

Levetiracetam works by binding to the synaptic vesicle protein SV2A, which modulates the release of neurotransmitters. This action stabilizes neuronal firing and lowers hyper‑excitability, thereby preventing the spread of abnormal electrical activity that leads to seizures.

The dose of levetiracetam is individualized. A qualified prescriber determines the appropriate amount based on the patient’s age, weight, renal function, seizure type, and response to therapy. Patients should follow the prescribing information provided by their healthcare professional.

Safety data for levetiracetam in pregnancy are limited, and the drug is classified as pregnancy category unknown. It should be used only if the potential benefit outweighs the risk. During breastfeeding, the medication may pass into milk; a clinician should assess the risk‑benefit ratio for the infant.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Levetiracetam offers a broad spectrum of seizure control with a relatively favorable interaction profile compared with many enzyme‑inducing antiepileptics. It does not require routine therapeutic drug monitoring and is generally well tolerated, though individual response and side‑effect profiles may differ from agents such as carbamazepine, valproate or phenytoin.

Levetiracetam Krka should be stored at temperatures below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Levetiracetam Krka is administered orally, typically as a tablet that can be swallowed whole with water. The exact dosing schedule—once daily, twice daily, or more—depends on the prescriber’s instructions and the patient’s clinical needs.

Serious risks include severe allergic reactions (such as rash, swelling, or breathing difficulty), significant mood changes (including depression, suicidal thoughts, or aggression), and rare hematologic or hepatic abnormalities. Patients should seek immediate medical attention if any of these symptoms arise.

Levetiracetam is contraindicated in individuals with known hypersensitivity to levetiracetam or any of its excipients. Caution is also advised for patients with severe renal impairment, uncontrolled psychiatric disorders, or those taking interacting medications that may markedly reduce its effectiveness.